Literature DB >> 18222915

Beta-microseminoprotein in serum correlates with the levels in seminal plasma of young, healthy males.

Camilla Valtonen-André1, Charlotta Sävblom, Per Fernlund, Hans Lilja, Aleksander Giwercman, Ake Lundwall.   

Abstract

Beta-microseminoprotein (MSP) is one of the most abundant proteins secreted by the prostate gland. Because MSP is also synthesized in nonreproductive organs, the establishment of a solid relationship between the levels of MSP in serum and semen is crucial for future studies connecting MSP with aging or diseases of the prostate gland. We developed a specific, competitive, europium-based immunoassay to measure MSP in serum and seminal plasma. We also produced recombinant MSP in insect cells using baculo virus and purified it to homogeneity by a novel approach with ethanol extraction and gel filtration. The median values of MSP in 205 young men were 12 microg/L (2.5-97.5 percentile, 4.9-26 microg/L) in serum and 0.53 g/L (2.5-97.5 percentile, 0.13-2.0 g/L) or 1.8 mg (2.5-97.5 percentile, 0.32-6.6 mg) in seminal plasma. MSP in serum showed significant correlation to MSP in seminal plasma (r = .50, P < .001). Significant correlations were also found in seminal plasma between MSP and prostate-specific antigen (PSA) (r = .65, P < .001) and between MSP and Zn(2+) (r = .54, P < .001). The yield of recombinant MSP in culture medium was 35 mg/L or higher, and recovery following ethanol extraction was 80%-90%. MSP in serum reflects the prostate secretion of MSP, and correlations were also found in seminal plasma between MSP and PSA and Zn(2+). This suggests that MSP in serum can be used as a marker of prostate secretion, despite the contribution from extra prostatic tissues.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18222915     DOI: 10.2164/jandrol.107.003616

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  12 in total

1.  Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts.

Authors:  Hong Lou; Hongchuan Li; Meredith Yeager; Kate Im; Bert Gold; Thomas D Schneider; Joseph F Fraumeni; Stephen J Chanock; Stephen K Anderson; Michael Dean
Journal:  Hum Genet       Date:  2012-06-04       Impact factor: 4.132

2.  Growth inhibition properties of the putative prostate cancer biomarkers PSP94 and CRISP-3.

Authors:  Aleyde Van Eynde; Kirill Litovkin; Mathieu Bollen
Journal:  Asian J Androl       Date:  2010-11-22       Impact factor: 3.285

3.  A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.

Authors:  Katharina Braun; Daniel D Sjoberg; Andrew J Vickers; Hans Lilja; Anders S Bjartell
Journal:  Eur Urol       Date:  2015-05-13       Impact factor: 20.096

4.  A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.

Authors:  Melissa Assel; Liisa Sjöblom; Teemu J Murtola; Kirsi Talala; Paula Kujala; Ulf-Håkan Stenman; Kimmo Taari; Anssi Auvinen; Andrew Vickers; Tapio Visakorpi; Teuvo L Tammela; Hans Lilja
Journal:  Eur Urol Focus       Date:  2017-11-11

5.  A common prostate cancer risk variant 5' of microseminoprotein-beta (MSMB) is a strong predictor of circulating beta-microseminoprotein (MSP) levels in multiple populations.

Authors:  Kevin M Waters; Daniel O Stram; Loic Le Marchand; Robert J Klein; Camilla Valtonen-André; Mari T Peltola; Laurence N Kolonel; Brian E Henderson; Hans Lilja; Christopher A Haiman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08-24       Impact factor: 4.254

6.  Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel.

Authors:  Eric H Kim; Gerald L Andriole; E David Crawford; Daniel D Sjoberg; Melissa Assel; Andrew J Vickers; Hans Lilja
Journal:  J Urol       Date:  2016-11-01       Impact factor: 7.450

7.  Polymorphisms at the Microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levels.

Authors:  Xing Xu; Camilla Valtonen-André; Charlotta Sävblom; Christer Halldén; Hans Lilja; Robert J Klein
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08       Impact factor: 4.254

8.  β-Microseminoprotein endows post coital seminal plasma with potent candidacidal activity by a calcium- and pH-dependent mechanism.

Authors:  Anneli M L Edström Hägerwall; Victoria Rydengård; Per Fernlund; Matthias Mörgelin; Maria Baumgarten; Alexander M Cole; Martin Malmsten; Birthe B Kragelund; Ole E Sørensen
Journal:  PLoS Pathog       Date:  2012-04-05       Impact factor: 6.823

9.  Rapidly evolving marmoset MSMB genes are differently expressed in the male genital tract.

Authors:  Ake Lundwall; Olivia Larne; Penelope L Nayudu; Yvonne Ceder; Camilla Valtonen-André
Journal:  Reprod Biol Endocrinol       Date:  2009-09-09       Impact factor: 5.211

10.  Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.

Authors:  Liisa Sjöblom; Outi Saramäki; Matti Annala; Katri Leinonen; Janika Nättinen; Teemu Tolonen; Tiina Wahlfors; Matti Nykter; G Steven Bova; Johanna Schleutker; Teuvo L J Tammela; Hans Lilja; Tapio Visakorpi
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.